The Radionuclide Therapy and Dosimetry Research Lab is focused on modeling and dosimetry analysis of radionuclide therapy to support the translation of novel targeted radionuclide therapy strategies to the clinic. The research is divided between laboratory studies and patient-specific dosimetry, radiobiological modeling studies, alpha-particle dosimetry, and mathematical modeling of radionuclide therapy. The lab is currently engaged in pre-clinical research investigating targeted alpha-emitter therapy of metastatic cancer.

The Radiopharmaceutical Therapy and Dosimetry (RTD) Lab has two missions: 1. Support clinical Radiopharmaceutical Therapy (RPT) trials by performing patient-specific dosimetry and developing novel methods that advance this field and illustrate the impact of a precision medicine approach to implementing treatment planning in RPT. This includes radiobiological modeling and microscale dosimetry calculations for alpha-particle emitter RPT. 2. Pre-clinical studies using novel alpha-emitter RPT agents with immune intact transgenic animal models that incorporate modeling and dosimetry to support the translation of novel targeted radionuclide therapy strategies to the clinic. In particular, identifying how to best combine RPT with complementary orthogonal-modality agents while also obtaining a basic understanding of how the treatment works and which variables have the greatest impact on efficacy and toxicity. The underlying objective is to utilize pre-clinical modeling and dosimetry to help identify an optimal therapeutic clinical trial design so as to reduce unnecessary human experimentation.